CU6 — Clarity Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$695.59m
- AU$517.34m
Brief: Clarity Pharma Updates On Phase III Trial Of 64 Cu Sar-Bispsma Diagnostic In Prostate Cancer
Brief: Clarity Commences Combat Theranostic Prostate Cancer Trial In The US
Australia's Clarity Pharmaceuticals rises on PETNET Solutions agreement
Brief: Clarity Pharmaceuticals Expands Supply Of Cu-64 Sar-Bispsma For Pivotal Phase Iii Clinical Trials
Brief: Clarity's Theranostic Prostate Cancer Trial Advances To Cohort 2
Brief: Clarity Pharmaceuticals Confirms No Supply Interruptions
Brief: Clarity Pharmaceuticals Posts HY Loss Attributable Of A$11.2 Million
Brief: Us Based Cobra Diagnostic Prostate Cancer Trial Reaches Recruitment Target
Australia's Clarity Pharmaceuticals jumps as cancer drug gets U.S. FDA nod
Brief: Clarity Pharmaceuticals Says It Got IND Approval By US FDA For Theranostic Sar-Bombesin Trial
Brief: First Patient Treated In Clarity's Therapeutic Prostate Cancer Trial
Brief: First Participant Imaged In Phase Ii Sar-Bombesin Prostate Cancer Trial In The US
Brief: Clarity Pharmaceuticals Says Patent Application Granted In China
Brief: Clarity Pharmaceuticals Says FY Loss From Ordinary Activities After Tax Attributable A$23.8 Mln
Brief: Clarity Advances To Cohort 3 Of CL04 Trial Of Sartate In Paediatric Neuroblastoma
Brief: Clarity Pharmaceuticals Says It Got IND Approval By U.S. FDA For Phase II SAR-Bombesin Trial
Australia's Clarity Pharmaceuticals hits 3-1/2 week high on nanobody platform buy
Brief: Clarity Pharmaceuticals Announces Acquisition Of Targeted Nanobody Platform
Brief: Clarity Pharmaceuticals Confirms No Supply Issues To Its Clinical Trials